AA
TAK icon

AlphaCentric Advisors’s Takeda Pharmaceutical TAK Stock Holding History

AlphaCentric Advisors’s Portfolio TAK Stock Details TAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-80,000
Closed -$1.14M – 278
2024
Q3 		$1.14M Buy
+80,000
New +$1.13M 0.85% 41
2021
Q3 		– Sell
-2,200
Closed -$37K – 217
2021
Q2 		$37K Hold
2,200
– – 0.01% 204
2021
Q1 		$40K Hold
2,200
– – 0.01% 201
2020
Q4 		$40K Hold
2,200
– – 0.02% 190
2020
Q3 		$39K Hold
2,200
– – 0.02% 121
2020
Q2 		$39K Buy
+2,200
New +$39.5K 0.02% 96

Other funds holding TAK

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
VanEck Associates
VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AlphaCentric Advisors's TAK Position: Q4 2024 in Review

AlphaCentric Advisors sold out of Takeda Pharmaceutical (TAK) in Q4 2024, closing a stake of 80,000 shares — an estimated $1.14M sold.

AlphaCentric Advisors first reported a position in TAK in Q2 2020 and held it in 6 quarters. The position peaked at $1.14M in Q3 2024. 299 funds tracked by Wall St. Rank hold TAK as of Q4 2024.

  • AlphaCentric Advisors reported no remaining Takeda Pharmaceutical position as of Q4 2024 after selling out during the quarter.
  • AlphaCentric Advisors sold 80,000 Takeda Pharmaceutical shares in Q4 2024, an estimated $1.14M.
  • AlphaCentric Advisors first reported a position in Takeda Pharmaceutical in Q2 2020 and held it in 6 quarters.
  • AlphaCentric Advisors's Takeda Pharmaceutical position peaked at $1.14M in Q3 2024.
  • 299 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q4 2024.

Based on AlphaCentric Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.